Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Pablo Corral: Pushing the Limits of LDLc: Emerging Paradigms in CV Risk Reduction
Pablo Corral/LinkedIn
Oct 29, 2025, 07:39

Pablo Corral: Pushing the Limits of LDLc: Emerging Paradigms in CV Risk Reduction

Pablo Corral, Past President of Argentine Lipid Society, has shared a post on LinkedIn:

“Pushing the limits of LDLc: Emerging paradigms in CV risk reduction

  1. Modern guidelines now target LDL-C <55 mg/dL, and even <40 mg/dL for the highest-risk patients.
  2. Evidence from FOURIER, ODYSSEY, and IMPROVE-IT confirms that the lower, the better — with no safety concerns, even below 25 mg/dL.
  3. Genetic data (PCSK9 LoF, APOB, ANGPTL3) reinforce that lifelong low LDL-C protects against ASCVD.
  4. Emerging therapies — PCSK9 inhibitors, inclisiran, bempedoic acid, ANGPTL3 inhibitors — make these targets achievable.
  5. Cognitive, endocrine, and hemorrhagic risks remain none at very low LDL-C.

The real challenge is no longer how low can we go, but how many actually get there.”

Pablo Corral: Pushing the Limits of LDLc: Emerging Paradigms in CV Risk Reduction

Stay updated with Hemostasis Today.

ANGPTL3 APOB Argentine Lipid Society ASCVD European Atherosclerosis Society Health Hematology Hemostasis Hemostasis Today LDL-C Medicine Pablo Corral PCSK9 LoF
NewsFeed